Brokerages Set Dianthus Therapeutics, Inc. (NASDAQ:DNTH) PT at $54.33

Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) have been assigned an average rating of “Buy” from the nine research firms that are presently covering the firm, Marketbeat reports. Seven analysts have rated the stock with a buy rating and two have issued a strong buy rating on the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $54.33.

Several research firms recently issued reports on DNTH. TD Cowen began coverage on Dianthus Therapeutics in a report on Friday, December 20th. They set a “buy” rating on the stock. Raymond James upgraded Dianthus Therapeutics to a “moderate buy” rating in a research note on Thursday, December 12th. Guggenheim reissued a “buy” rating and issued a $84.00 target price on shares of Dianthus Therapeutics in a research note on Wednesday, March 12th. Wedbush reaffirmed an “outperform” rating and set a $36.00 price target on shares of Dianthus Therapeutics in a research report on Wednesday, March 12th. Finally, HC Wainwright reissued a “buy” rating and issued a $40.00 price objective on shares of Dianthus Therapeutics in a research report on Wednesday, March 12th.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of DNTH. TCG Crossover Management LLC acquired a new position in shares of Dianthus Therapeutics in the fourth quarter valued at approximately $32,735,000. Braidwell LP grew its holdings in Dianthus Therapeutics by 144.4% in the 4th quarter. Braidwell LP now owns 1,206,589 shares of the company’s stock valued at $26,304,000 after buying an additional 712,902 shares in the last quarter. Vestal Point Capital LP lifted its holdings in shares of Dianthus Therapeutics by 172.2% during the fourth quarter. Vestal Point Capital LP now owns 1,075,000 shares of the company’s stock worth $23,435,000 after buying an additional 680,000 shares in the last quarter. State Street Corp boosted its position in shares of Dianthus Therapeutics by 101.4% in the third quarter. State Street Corp now owns 821,131 shares of the company’s stock valued at $22,483,000 after acquiring an additional 413,425 shares during the period. Finally, Octagon Capital Advisors LP boosted its position in shares of Dianthus Therapeutics by 20.8% in the fourth quarter. Octagon Capital Advisors LP now owns 2,110,167 shares of the company’s stock valued at $46,002,000 after acquiring an additional 363,500 shares during the period. 47.53% of the stock is owned by institutional investors.

Dianthus Therapeutics Stock Down 4.8 %

NASDAQ:DNTH opened at $14.86 on Friday. The company has a market cap of $477.38 million, a P/E ratio of -5.94 and a beta of 1.62. Dianthus Therapeutics has a twelve month low of $14.60 and a twelve month high of $32.27. The business has a 50 day moving average price of $21.12 and a two-hundred day moving average price of $23.65.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its quarterly earnings data on Tuesday, March 11th. The company reported ($0.81) EPS for the quarter, topping analysts’ consensus estimates of ($0.85) by $0.04. Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. The business had revenue of $1.33 million for the quarter, compared to analyst estimates of $1.40 million. As a group, analysts anticipate that Dianthus Therapeutics will post -2.61 earnings per share for the current fiscal year.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.